Canada: Federal Court Of Appeal Considers Data Protection Provisions…Again

The recent decision of the Federal Court of Appeal (FCA) in Minister of Health v. Celgene Inc. (Celgene) marks the second split decision of that court in as many months on the data protection provision of the Food and Drug Regulations (the FDR).

Our previous bulletin, Closer Than They Appear: Federal Court of Appeal Considers Definition of "Innovative Drug", reported on the decision of the FCA in Takeda Canada Inc. v. The Minister of Health (Takeda), denying data protection for Takeda's DEXILANT drug on the ground that it did not qualify as an "innovative drug". Although the FCA in Celgene considered a different aspect of the definition of "innovative drug", data protection was also denied on the ground that the product at issue in that case did not fall within the definition.


The question in the Celgene appeal was whether Celgene's THALOMID drug falls within the definition of an "innovative drug" in the FDR. Under the FDR, an innovative drug, once approved by the Minister of Heath (the Minister) by way of a Notice of Compliance (NOC), is listed on the Register of Innovative Drugs (the Register).

Under the FDR, an approved drug that is listed on the Register benefits from a period of market exclusivity for eight years starting from the date of approval. During that period, a generic manufacturer may not obtain an NOC to market a drug based on the data filed with Health Canada for approval of the innovative drug.

In the FDR, an "innovative drug" is defined as "a drug that contains a medicinal ingredient not previously approved in a drug by the Minister and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph" [emphasis added].


In the Federal Court of Canada (FCC), Celgene challenged the Minister's decision not to list THALOMID on the Register. The FCC considered whether the prior approval of thalidomide in the early 1960s constituted an approval within the definition of "innovative drug" in the FDR. Shortly after its first approval in November 1960, thalidomide was withdrawn from the Canadian market in April 1962 due to the determination that the drug caused serious side effects, most significantly severe birth defects.

The FCC held that THALOMID was an "innovative drug" and should be listed on the Register and benefit from the eight years of data protection. The FCC looked at the purpose and intent of the FDR to encourage innovation and the development of new drugs, and found that Celgene had taken a compound that had been banned and had produced entirely new data showing that the drug could be useful and potentially lifesaving under the right circumstances.

The FCC further held that to deny data protection in this case would be inconsistent with Canada's international treaty obligations under the North American Free Trade Agreement and the Agreement on Trade-Related Aspects of Intellectual Property Rights. For further discussion of the FCC decision, please see our October 2012 Blakes Bulletin on Life Sciences: I Want a New Drug: Developments in Data Protection for Innovative Drugs.


In a split decision, the FCA reversed the FCC and held that THALOMID does not qualify as an "innovative drug." Celgene argued that the word "approved" refers to the status of the drug at the time the request for approval of the drug is submitted by the innovator, effectively interpreting the term "previously approved" as "currently approved". Writing for the majority, Justice Gauthier held that the words did not lend themselves to this interpretation and further disagreed with Celgene's argument that such an interpretation was consistent with the intention of the FDR and the relevant treaty provisions. Justice Gauthier applied a literal interpretation of the term "previously approved".

Justice Gauthier stated that the legislators clearly intended to avoid any duplication of the market exclusivity period and that, while there may be no such duplication in this case, this would not necessarily be true if Celgene's interpretation of the term "previously approved" to mean "currently approved" were applied in all cases. She also noted that Celgene's interpretation could apply to any drug which had been withdrawn because of a Minister's decision or even to a drug that was voluntarily withdrawn. While Justice Gauthier acknowledged the exceptional history of thalidomide, she found that this history did not provide sufficient basis to create an exception in the interpretation of the FDR.

Justice Nadon dissented from the majority and would have dismissed the appeal and upheld the decision of the FCC to grant data protection. Like the majority, Justice Nadon focused on the interpretation of the term "previously approved". However, he held that the circumstances surrounding the revocation of thalidomide's approval and removal from the Canadian market in 1962 amounted to a "nullification" of the previous approval so that thalidomide was not "previously approved" and was eligible for data protection.

Although Justice Nadon would have upheld the decision of the FCC, he explicitly distanced his view from the reasoning of the FCC. Specifically, while he found that the FCC's focus on the purpose and intent of the data protection regime was "helpful, and concurrent in result", it was not determinative of his holdings on appeal since his position could be supported merely by a proper interpretation of "previously approved".

Nonetheless, Justice Nadon's reasons do consider the purpose and intention of the data protection regime. In particular, he highlighted that, given thalidomide's revoked approval, there was no product available to serve as a reference product for THALOMID. As such, Celgene was required to prepare and submit the voluminous data required to support a New Drug Submission rather than the Abbreviated New Drug Submission that a generic manufacturer would be able to submit. Justice Nadon found that this bolstered the rationale for extending data protection to THALOMID.

Justice Nadon's strong dissent in this case follows the dissent of Justice Stratas in the Takeda case. Although the cases focused on different aspects of the definition of "innovative drug", in both cases the majority decision held that the literal meaning of the definition was clear. Although both majority decisions considered the purpose of the legislation, including compliance with Canada's international treaty obligations, the decisions turned on the view that the wording of the statutory provision was, on its face, unambiguous.

The dissenting justices in each case, while not expressly adopting a different approach to the interpretation of the statute, appeared to give greater weight to the underlying purpose and context of the statutory provisions and would have adopted an approach that would have more specifically taken into account the amount of time, effort and resources expended by the drug manufacturers when deciding whether to extend data protection.

The majority decisions in these cases, which emphasize the literal interpretation of the statutory provisions, clearly set the precedent for future cases dealing with the data protection regime in the FDR. However, the strong dissents in these cases do illustrate that some uncertainty may still exist when interpreting these provisions.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
1 Nov 2016, Seminar, Toronto, Canada

What is the emotional culture of your organization?

Every organization and workplace has an emotional culture that can have an impact on everything from employee performance to customer or client satisfaction.

3 Nov 2016, Seminar, Toronto, Canada

Join leading lawyers from the Blakes Pensions, Benefits & Executive Compensation group as they discuss recent updates and legal developments in pension and employee benefits law as well as strategies to identify and minimize common risks.

3 Nov 2016, Other, Vancouver, Canada

“Risk” is the new black. It’s on the lips of every CEO, CFO, GC and board member — as it should be. Can you spot it? How do you analyze it? Are you equipped to manage it?

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.